{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:15:11Z","timestamp":1767633311001,"version":"3.48.0"},"reference-count":48,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Horizon 2020 program of the European Union","award":["823839"],"award-info":[{"award-number":["823839"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neoadjuvant chemotherapy (NACT) is the standard treatment for muscle-invasive bladder carcinoma (MIBC), but its efficacy varies significantly among patients. The aim of this study is the identification of biomarkers and biological processes related to the response to neoadjuvant chemotherapy (NACT) in muscle-invasive bladder carcinoma (MIBC). Fifty-eight transurethral resection (TURBT) samples and thirty cystectomy samples from NACT non-responders were analyzed using mass spectrometry. Samples were classified with sparse k-means and consensus clustering. Protein networks were built using probabilistic graphical models, grouped into functional nodes, and analyzed for activity differences. Gene set enrichment analysis was applied to identify resistance mechanisms, and results were validated using The Cancer Genome Atlas (TCGA) cohort. Proteomic analysis revealed two independent classifications in TURBT samples. The first (Layer1) divided tumors into three groups, including one NACT non-responder subtype not aligned with traditional luminal or basal classifications but characterized by high expression of targetable markers NECTIN4 and Her2. The second (Layer3) separated luminal-papillary tumors from luminal-infiltrated\/luminal and basal tumors. While Layer3 groups did not differ in NACT response, they showed distinct disease-free survival outcomes. Importantly, complete response to NACT was linked to improved survival in luminal subgroups but not in basal tumors, suggesting subtype-specific prognostic implications. Finally, analysis of cystectomy samples identified unique mechanisms of resistance for each subgroup, suggesting tailored therapeutic approaches. Two classification systems were defined as follows: one identified a proteomics-based non-responder group with actionable targets, and the other linked tumor subtype to prognosis. Distinct resistance mechanisms suggest opportunities for subtype-specific therapies, supporting improved management and treatment development for MIBC patients.<\/jats:p>","DOI":"10.3390\/ijms27010476","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:23:44Z","timestamp":1767356624000},"page":"476","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-3474","authenticated-orcid":false,"given":"Luc\u00eda","family":"Trilla-Fuertes","sequence":"first","affiliation":[{"name":"Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Pedregosa-Barbas","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-1906","authenticated-orcid":false,"given":"Eugenia","family":"Garc\u00eda-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Pathology, La Paz University Hospital-IdiPAZ, UAM, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Zambrana","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Infanta Sof\u00eda University Hospital, 28702 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imanol","family":"Mart\u00ednez-Salas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, IIS-FJD, University Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5156-7080","authenticated-orcid":false,"given":"Pablo","family":"Gajate","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3726-050X","authenticated-orcid":false,"given":"Fernando","family":"Becerril-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Lalanda-Delgado","sequence":"additional","affiliation":[{"name":"Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-5192","authenticated-orcid":false,"given":"Antje","family":"Dittmann","sequence":"additional","affiliation":[{"name":"Functional Genomics Center Zurich, University of Zurich\/ETH Zurich, 8057 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"L\u00f3pez-Vacas","sequence":"additional","affiliation":[{"name":"Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kunz","sequence":"additional","affiliation":[{"name":"Functional Genomics Center Zurich, University of Zurich\/ETH Zurich, 8057 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Rubio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Infanta Sof\u00eda University Hospital, 28702 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Nieto-Torrero","sequence":"additional","affiliation":[{"name":"IdiPAZ Biobank, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Pertejo","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Gonz\u00e1lez-Peramato","sequence":"additional","affiliation":[{"name":"Department of Pathology, La Paz University Hospital-IdiPAZ, UAM, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-1252","authenticated-orcid":false,"given":"Juan \u00c1ngel","family":"Fresno Vara","sequence":"additional","affiliation":[{"name":"Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"},{"name":"Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-0624","authenticated-orcid":false,"given":"Angelo","family":"G\u00e1mez-Pozo","sequence":"additional","affiliation":[{"name":"Molecular Oncology Lab, INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"},{"name":"Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-053X","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Pinto-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Cathomas","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Trilla-Fuertes, L., G\u00e1mez-Pozo, A., Prado-V\u00e1zquez, G., Zapater-Moros, A., D\u00edaz-Almir\u00f3n, M., Arevalillo, J.M., Ferrer-G\u00f3mez, M., Navarro, H., Ma\u00edn, P., and Espinosa, E. (2019). Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5858-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15819","DOI":"10.1038\/s41598-017-15920-6","article-title":"Urothelial cancer proteomics provides both prognostic and functional information","volume":"7","author":"Urbanowicz","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2023.05.037","article-title":"Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors","volume":"85","author":"Groeneveld","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1038\/s41467-024-48096-5","article-title":"Proteomic analysis of the urothelial cancer landscape","volume":"15","author":"Dressler","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Camacho, E., Prado-V\u00e1zquez, G., Mart\u00ednez-P\u00e9rez, D., Ferrer-G\u00f3mez, M., Llorente-Armijo, S., L\u00f3pez-Vacas, R., D\u00edaz-Almir\u00f3n, M., G\u00e1mez-Pozo, A., Vara, J.F., and Feliu, J. (2023). A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities. Cancers, 15.","DOI":"10.1101\/2023.01.13.23284526"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41598-018-38364-y","article-title":"A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses","volume":"9","author":"Arevalillo","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-012-2192-4","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Follow-up analysis from the randomized \u2018FIRST\u2019 study","volume":"136","author":"Robertson","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Petrella, G., Ciufolini, G., Vago, R., and Cicero, D.O. (2020). The Interplay between Oxidative Phosphorylation and Glycolysis as a Potential Marker of Bladder Cancer Progression. Int. J. Mol. Sci., 21.","DOI":"10.21203\/rs.3.rs-81513\/v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/sji.12329","article-title":"Clinical Role of Human Leukocyte Antigen in Health and Disease","volume":"82","author":"Mosaad","year":"2015","journal-title":"Scand. J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"237.e21","DOI":"10.1016\/j.urolonc.2020.11.017","article-title":"A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer","volume":"39","author":"Piao","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101224","DOI":"10.1016\/j.xcrm.2023.101224","article-title":"Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer","volume":"4","author":"Kim","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.eururo.2024.06.023","article-title":"Membranous expression of target protein is required for ADC response in urothelial cancer","volume":"87","author":"Bahlinger","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR Inhibition in Urothelial Carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1611117","DOI":"10.3389\/pore.2023.1611117","article-title":"Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy","volume":"29","author":"Fan","year":"2023","journal-title":"Pathol. Oncol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41598-021-04678-7","article-title":"Upregulation of IFN\u03b3-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma","volume":"12","author":"Hodgson","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_33","first-page":"258","article-title":"Role of angiogenesis in urothelial bladder carcinoma","volume":"69","author":"Fus","year":"2016","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11912-023-01421-5","article-title":"An Overview of Angiogenesis in Bladder Cancer","volume":"25","author":"Elayat","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1758834016667179","article-title":"Incorporating VEGF-targeted therapy in advanced urothelial cancer","volume":"9","author":"Narayanan","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1158\/0008-5472.CAN-14-1937","article-title":"Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications","volume":"75","author":"Arevalillo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/prca.201200048","article-title":"Shotgun proteomics of archival triple-negative breast cancer samples","volume":"7","author":"Ferrer","year":"2013","journal-title":"Proteom. Clin. Appl."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"T\u00fcrker, C., Akal, F., Joho, D., Panse, C., Barkow-Oesterreicher, S., Rehrauer, H., and Schlapbach, R. (2010). B-Fabric: The Swiss Army Knife for Life Sciences. Proceedings of the 13th International Conference on Extending Database Technology (EDBT \u201810), Association for Computing Machinery.","DOI":"10.1145\/1739041.1739135"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","article-title":"DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput","volume":"17","author":"Demichev","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The Perseus computational platform for comprehensive analysis of (prote)omics data","volume":"13","author":"Tyanova","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acid Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1198\/jasa.2010.tm09415","article-title":"A framework for feature selection in clustering","volume":"105","author":"Witten","year":"2010","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lauritzen, S. (1996). Graphical Models, Oxford University Press.","DOI":"10.1093\/oso\/9780198522195.001.0001"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v037.i01","article-title":"High-Dimensional Graphical Model Search with the gRapHD R Package","volume":"37","author":"Abreu","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"P10008","DOI":"10.1088\/1742-5468\/2008\/10\/P10008","article-title":"Fast unfolding of communities in large networks","volume":"10","author":"Blondel","year":"2008","journal-title":"J. Stat. Mech. Theory Exp."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:41:55Z","timestamp":1767616915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27010476"],"URL":"https:\/\/doi.org\/10.3390\/ijms27010476","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}